POTENTIALLY available within two to three years, established diabetes drugs Byetta (exenatide), Bydureon (exenatide extended release) from AstraZeneca and Victoza (liraglutide) by Novo Nordisk are looking like the new hope for Alzheimers disease (AD) patients, according to new work published in Brain Research.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jan 18
